ClinicalTrials.Veeva

Menu

A Study of OPC-262 in Patients With Type 2 Diabetes

Kyowa Kirin logo

Kyowa Kirin

Status and phase

Completed
Phase 3

Conditions

Type 2 Diabetes

Treatments

Drug: OPC-262

Study type

Interventional

Funder types

Industry

Identifiers

NCT01046318
JapicCTI-090952 (Registry Identifier)
262-09-004

Details and patient eligibility

About

The purpose of this clinical study is to evaluate the safety and efficacy of OPC-262 5 mg in patients with type 2 diabetes by repeated administration orally for 52 weeks.

Enrollment

100 patients

Sex

All

Ages

20 to 74 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Type 2 diabetes patients with HbA1C above 6.5% and below 10% at both of the time of the 1st and the 2nd screening examinations and who have been undergoing diet and exercise therapies only for at least 8 weeks prior to the 1st screening examination
  2. Patients who are capable of giving informed consent
  3. Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after the study (end of the post-observation period)

Exclusion criteria

  1. Patients with type 1 diabetes mellitus, patients with diabetes mellitus due to other specified drugs, mechanisms or diseases, and patients with gestational diabetes mellitus
  2. Patients with a medical history of diabetic coma
  3. Patients with poorly-controlled hypertension
  4. Patients with heart failure
  5. Patients with a complication of active hepatitis or hepatic cirrhosis
  6. Patients undergoing treatment of glomerular diseases other than diabetic nephropathy
  7. Patients with a history or complication of malignant tumor

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

100 participants in 1 patient group

OPC-262 5 mg
Experimental group
Description:
OPC-262 5 mg will be orally administered once daily fro 52 weeks.
Treatment:
Drug: OPC-262

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems